Is Krystal Biotech, Inc. (KRYS) a Buy, Sell, or Hold?
Krystal Biotech, Inc.
NASDAQ:KRYS
$339.43 USD
-$24.01 (-6.61%)
- Volume
- 498.78K
- Average Volume
- 315.3K
- Market Capitalization
- $10.01B
- P/E Ratio
- 43.80
- Dividend Yield
- 0.00%
- Price Target
- $327.00
- Year High
- $382.54
- Year Low
- $130.50
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.46
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Krish S. Krishnan |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | KRYS |
| CUSIP | 501147102 |
| CIK | 0001711279 |
| Web | https://www.krystalbio.com |
| Phone | 412 586 5830 |
| Currency | USD |
| Employees | 295 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 9.46 |
| Quick Ratio | 9.06 |
| Cash Ratio | 4.65 |
Sales & Book Value
| Annual Sales | $389.13M |
| Price / Sales | 23.98 |
| Cash Flow | 8.11 |
| Price / Cash Flow | 42.15 |
| Price / Book | 7.79 |
Price Target and Rating
| Average Stock Price Forecast | $327.00 |
| High Stock Price Forecast | $474.00 |
| Low Stock Price Forecast | $300.00 |
| Forecast Upside/Downside | 3.80% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 17 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $6.84 |
| Trailing P/E Ratio | 43.80 |
| PEG Ratio | 0.55 |
| P/E Growth | 0.55 |
| Net Income | $204.83M |
| Net Margin | 53.92% |
| Pretax Margin | 49.68% |
| Return on Equity | 19.25% |
| Return on Assets | 16.11% |
Financials Score
| AltmanZ Score | 55.09 |
| Piotroski Score | 5.00 |
| Working Capital | 911.94M |
| Total Assets | 1.4B |
| Ebit | 194.03M |
| Market Cap | 10.71B |
| Total Liabilities | 120.24M |
Poll Results
About Krystal Biotech, Inc. (NASDAQ:KRYS) Stock
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier d ... iscovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
3 Soaring Stocks That May Have More Upside Ahead
2026-07-07 19:15:00
The sky is the limit for these companies.
Krystal Biotech (KRYS) Soars 3.4%: Is Further Upside Left in the Stock?
2026-06-29 09:51:05
Krystal Biotech (KRYS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Entertainment Stocks Madison Square Garden, Sphere Rally To New Highs
2026-06-26 14:40:22
Entertainment leader Sphere stock continues to outperform in the current market environment, setting new highs.
3 Biotech Firms With Major Potential Catalysts in the Coming Months
2026-06-23 17:35:11
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
3 Biotech Firms With Major Potential Catalysts in the Coming Months
2026-06-21 10:31:44
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead
2026-06-18 01:30:00
Moderna is racing towards important clinical and regulatory catalysts. Krystal Biotech still has a large market to address in its core area.
Is the Options Market Predicting a Spike in Krystal Biotech Stock?
2026-06-05 13:00:46
Investors need to pay close attention to KRYS stock based on the movements in the options market lately.
Krystal Biotech Stock Soars 16% in Three Months: Here's Why
2026-06-04 11:31:09
KRYS shares climb 16% in three months as Vyjuvek revenues jump 32%, pipeline programs advance and a nearly $1B cash pile fuels confidence.
Frequently Asked Questions
-
What is the current Krystal Biotech, Inc. (KRYS) stock price?
-
Krystal Biotech, Inc.(NASDAQ:KRYS) stock price is $339.43 in the last trading session. During the trading session, KRYS stock reached the peak price of $382.535 while $130.5 was the lowest point it dropped to. The percentage change in KRYS stock occurred in the recent session was --6.61% while the dollar amount for the price change in KRYS stock was -$-24.01.
-
KRYS's industry and sector of operation?
-
The NASDAQ listed KRYS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of KRYS?
-
John Thomas | EVP, General Counsel & Corporate Secretary
Kathryn A. Romano | Executive Vice President & Chief Accounting Officer
John Karakkal | Vice President of North American Sales & Marketing
Josh Suskin | Senior Director & Head of US Human Resources
Krish S. Krishnan | Founder, Chairman, President & Chief Executive Officer -
How many employees does KRYS have?
-
Number of KRYS employees currently stands at 295. KRYS operates from 2100 Wharton Street, Pittsburgh, PA 15203, US.
-
Link for KRYS official website?
-
Official Website of KRYS is: https://www.krystalbio.com
-
How do I contact KRYS?
-
KRYS could be contacted at phone #412 586 5830 and can also be accessed through its website. KRYS operates from 2100 Wharton Street, Pittsburgh, PA 15203, US.
-
How many shares of KRYS are traded daily?
-
The average number of KRYS shares traded daily for last 3 months was 315.3K.
-
What is the market cap of KRYS currently?
-
The market value of KRYS currently stands at $10.01B with its latest stock price at $339.43